TransMed7 LLC (TransMed7) is a medical technology company that develops and manufactures biopsy devices. The company provides handheld soft tissue biopsy, stereotactic soft tissue biopsy, fine needle biopsy, vascular intervention, excisional soft tissue biopsy, prostate soft tissue biopsy, endoscopic soft tissue biopsy, robotic soft tissue biopsy, bone marrow biopsy, and laparoscopic biopsy. Its stereotactic soft tissue biopsy is used in the field of breast health. The company’s fine needle biopsy is used in lymph node, thyroid, liver, pancreas, and kidney biopsy applications. TransMed7 is headquartered in Phoenix, Arizona, the US
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company TransMed7 LLC
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
TransMed7 LLC Company Overview
TransMed7 LLC Company Snapshot
TransMed7 LLC Pipeline Products and Ongoing Clinical Trials Overview
TransMed7 LLC – Pipeline Analysis Overview
TransMed7 LLC - Key Facts
TransMed7 LLC - Major Products and Services
TransMed7 LLC Pipeline Products by Development Stage
Sep 06, 2023: TransMed7 Announces First Revenue from Concorde Family of Devices
Mar 21, 2023: TransMed announces first clinical use of VacuPac, a new self-contained, vacuum-assist attachment for all of its vacuum-assisted, Single Insertion - Multiple Collection (SIMC) platforms of biopsy devices
Feb 06, 2023: TransMed7 announces first clinical cases of Concorde Soft Tissue Biopsy Devices for Commercial Launch
Aug 16, 2022: TransMed7 announces first clinical use of Heron soft tissue biopsy devices for commercial launch
Aug 09, 2022: TransMed7 announces first clinical use of SpeedBird breast biopsy devices for commercial launch
Sep 22, 2020: TransMed7 announces first results from clinical use of its vacuum-assisted, Single Insertion - Multiple Collection (SIMC) platform of breast biopsy devices
Sep 01, 2020: TransMed7 announces 510(k) clearance by the U.S. FDA for its Concorde US (Ultrasound) and Concorde ST (Stereotactic) Soft Tissue Biopsy Device Platform
Sep 18, 2018: TransMed7 announces the availability of Concorde, the stereotactic table variant of its SpeedBird Biopsy device platform
Jul 30, 2018: TransMed7, LLC Names Dr. John Simpson as Strategic Advisor to Its Board of Directors
Jun 20, 2018: TransMed7 Announces 510(k) Clearance by the U.S. FDA for its SpeedBird Soft Tissue Biopsy Device Platform